«

»

How Might the FDA’s Approval of a New Alzheimer’s Drug Impact Medicaid?

The brief examines the potential impact of Aduhelm, a newly approved drug for Alzheimer's disease, on state and federal Medicaid costs and looks at potential policy actions that could limit Medicaid’s potential costs.

Read the full post at Reports on Health Insurance and Health Care Costs from the Kaiser Family Foundation
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive